These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 21973303)

  • 21. Polymyxins and their novel derivatives.
    Vaara M
    Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antimicrobial therapy in severe infections with multidrug-resistant Gram-negative bacterias].
    Duszyńska W
    Anestezjol Intens Ter; 2010; 42(3):160-6. PubMed ID: 21413423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues.
    Cornaglia G; Akova M; Amicosante G; Cantón R; Cauda R; Docquier JD; Edelstein M; Frère JM; Fuzi M; Galleni M; Giamarellou H; Gniadkowski M; Koncan R; Libisch B; Luzzaro F; Miriagou V; Navarro F; Nordmann P; Pagani L; Peixe L; Poirel L; Souli M; Tacconelli E; Vatopoulos A; Rossolini GM;
    Int J Antimicrob Agents; 2007 Apr; 29(4):380-8. PubMed ID: 17223319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections.
    Huwaitat R; McCloskey AP; Gilmore BF; Laverty G
    Future Microbiol; 2016 Jul; 11():955-72. PubMed ID: 27357521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Beta-lactamases of Gram negative bacteria: never-ending clockwork!].
    Philippon A; Arlet G
    Ann Biol Clin (Paris); 2006; 64(1):37-51. PubMed ID: 16420989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
    Levin AS; Oliveira MS
    Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.
    Bassetti M; Righi E
    Curr Opin Crit Care; 2015 Oct; 21(5):402-11. PubMed ID: 26263298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to polymyxins: Mechanisms, frequency and treatment options.
    Falagas ME; Rafailidis PI; Matthaiou DK
    Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of novel antibacterial drugs to combat multiple resistant organisms.
    Bassetti M; Righi E
    Langenbecks Arch Surg; 2015 Feb; 400(2):153-65. PubMed ID: 25667169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of resistance phenotypes in gram-negative bacteria].
    Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
    Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay.
    Sostarich AM; Zolldann D; Haefner H; Luetticken R; Schulze-Roebecke R; Lemmen SW
    Infection; 2008 Feb; 36(1):31-5. PubMed ID: 18231721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan.
    Saghir S; Faiz M; Saleem M; Younus A; Aziz H
    Indian J Med Microbiol; 2009; 27(4):341-7. PubMed ID: 19736404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of antibiotic resistance in the intensive care unit setting.
    Petrosillo N; Capone A; Di Bella S; Taglietti F
    Expert Rev Anti Infect Ther; 2010 Mar; 8(3):289-302. PubMed ID: 20192683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
    Hirsch EB; Tam VH
    J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.